Gemcitabine

For research use only. Not for use in humans.

製品コードS1714 別名:LY-188011, NSC 613327

Gemcitabine 化学構造

CAS No. 95058-81-4

Gemcitabine (LY-188011, NSC 613327), a nucleic acid synthesis inhibitor, is a very potent and specific deoxycytidine analogue, used as chemotherapy. Gemcitabine induces a potent p53-dependent apoptosis.

サイズ 価格(税別) 在庫  
10mM (1mL in DMSO) JPY 23500 あり
JPY 18100 あり
最寄りの販売代理店を探す

お探しのディーラーが見当たらない場合は直接こちらのメールアドレスまでお問い合わせください:[email protected]

バルク問合せ

文献中Selleckの製品使用例(119)

製品安全説明書

DNA/RNA Synthesis阻害剤の選択性比較

生物活性

製品説明 Gemcitabine (LY-188011, NSC 613327), a nucleic acid synthesis inhibitor, is a very potent and specific deoxycytidine analogue, used as chemotherapy. Gemcitabine induces a potent p53-dependent apoptosis.
体外試験

Gemcitabine results in 50% inhibition of growth in the CCRF-CEM human leukemia cell culture assay with IC50 of 1 ng/ml. Gemcitabine combined with deoxycytidine provides about a 1000-fold decrease in biological activity. [1] Gemcitabine combined with C225 results in additive cytotoxic effects that increased with increasing gemcitabine concentrations in human pancreatic carcinoma L3.6pl cells. [2] Gemcitabine combined with Cisplatin results in synergistic effect in wild-type A2780 and cisplatin-resistant ADDP cells. [3]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MV-4-11 NH6xcWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVfrO4lSUUN3ME2wMlAxODR3ODDuUS=> MnH2V2FPT0WU
ES4 NGHheFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV;uTVE4UUN3ME2wMlAxODZ3MzDuUS=> MoX2V2FPT0WU
ACHN M{XWN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NInKXmhKSzVyPUCuNFAxQDh5IH7N MnHhV2FPT0WU
KYSE-510 NHfPNJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVzJR|UxRTBwMECwPVc2KG6P M{\wXXNCVkeHUh?=
EW-7 Ml;qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEjibVNKSzVyPUCuNFAzPThibl2= MUfTRW5ITVJ?
BFTC-905 M1zJbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnXkTWM2OD1yLkCwOVE2KG6P M4nSVnNCVkeHUh?=
KE-37 MlHVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2P0e2lEPTB;MD6wNFU3OSCwTR?= Mki4V2FPT0WU
SBC-5 NYnBdYdVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn31TWM2OD1yLkCwOVchdk1? MWnTRW5ITVJ?
NKM-1 MmC4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHXGc|BKSzVyPUCuNFA4ODlibl2= MnTLV2FPT0WU
RH-1 NYX1c2Y6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml3STWM2OD1yLkCwO|E5KG6P MkSwV2FPT0WU
ALL-PO NHXoNZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXjJR|UxRTBwMEC4N{BvVQ>? MoHNV2FPT0WU
QIMR-WIL M{WwOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXPJR|UxRTBwMEC4PVQhdk1? NVSx[IpqW0GQR1XS
A375 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYHJR|UxRTBwMEC5PVUhdk1? M3\oeXNCVkeHUh?=
SIG-M5 M2TIN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWnERWNEUUN3ME2wMlAyODRibl2= NUTC[2p4W0GQR1XS
KGN MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH\uZmlKSzVyPUCuNFExQCCwTR?= MmKzV2FPT0WU
EW-13 NX\XXHp[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFHiZY5KSzVyPUCuNFEyOiCwTR?= NFS1fJFUSU6JRWK=
NCI-SNU-1 NV3pXoxOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4XMOWlEPTB;MD6wNVYhdk1? MknHV2FPT0WU
PSN1 NGDifmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWn2OWRjUUN3ME2wMlAyPjVibl2= MYXTRW5ITVJ?
HUTU-80 NVvxVpdQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYfJR|UxRTBwMEG2OkBvVQ>? NUfaSoR5W0GQR1XS
EW-16 NVHidnFXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnrsTWM2OD1yLkCyN{BvVQ>? NYq0NlBFW0GQR1XS
786-0 NUXV[|lVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXXJR|UxRTBwMEKzJI5O NUfxNYo{W0GQR1XS
ES1 Ml;ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWjFemZGUUN3ME2wMlAzPjhibl2= MoDFV2FPT0WU
RKO NUHCb2oxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmjwTWM2OD1yLkCyO|khdk1? M3jMPXNCVkeHUh?=
ESS-1 M{T0[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV\JR|UxRTBwMEK4OkBvVQ>? NH23RZJUSU6JRWK=
SK-UT-1 NV3UPINET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFnpUFZKSzVyPUCuNFI6PyCwTR?= MlywV2FPT0WU
LB2241-RCC NX\3UYhnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkjUTWM2OD1yLkCzNVghdk1? M3XSNXNCVkeHUh?=
CHL-1 NXzaXodXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUnJR|UxRTBwMEOyOEBvVQ>? NIjpRm5USU6JRWK=
SW1783 MnzrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHHyV3RKSzVyPUCuNFM{PiCwTR?= MXzTRW5ITVJ?
MEL-JUSO M3LXb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVTibpNsUUN3ME2wMlA{QTFibl2= M3vCc3NCVkeHUh?=
HT-29 NV3uT4VZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXTTZ4M6UUN3ME2wMlA1OTNibl2= NEDiVFlUSU6JRWK=
SNG-M M1[1TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFf1ZlVKSzVyPUCuNFQzPSCwTR?= NVnKWo1tW0GQR1XS
TE-15 NYfkdmFsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWfJR|UxRTBwMES2OEBvVQ>? NG[zSYtUSU6JRWK=
HOS MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUf2T5VXUUN3ME2wMlA1QCCwTR?= MmG5V2FPT0WU
BB65-RCC MnLRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYO2bVl2UUN3ME2wMlA2OTJibl2= NGG3bYZUSU6JRWK=
HCE-4 M4DzZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWjJR|UxRTBwMEWyPEBvVQ>? NY[wdGRUW0GQR1XS
MHH-ES-1 Ml3XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYX2PYhuUUN3ME2wMlA2OzFibl2= NVnmOm1WW0GQR1XS
RPMI-7951 NILEXWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEnMTYxKSzVyPUCuNFU1OSCwTR?= NGCwRoRUSU6JRWK=
IST-SL2 NIDzV49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXrJXnFZUUN3ME2wMlA2QDRibl2= MkH2V2FPT0WU
CMK NUfVfm0{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHz0VlFKSzVyPUCuNFU5PiCwTR?= M{i1VHNCVkeHUh?=
GR-ST MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWLJR|UxRTBwMEW5OUBvVQ>? NX7PPHV5W0GQR1XS
NALM-6 M133XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXXYSXNpUUN3ME2wMlA3OjJibl2= NWD3e5VoW0GQR1XS
RPMI-6666 NX3rU3BKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mki0TWM2OD1yLkC2OVIhdk1? M3S0PHNCVkeHUh?=
LC-2-ad Mmf1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVjJR|UxRTBwME[1N{BvVQ>? MXvTRW5ITVJ?
ARH-77 NUXNeJV2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1\VZmlEPTB;MD6wO|EyKG6P MoHzV2FPT0WU
IST-MEL1 NHzQV3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1XuRWlEPTB;MD6wO|I3KG6P NWPadZdSW0GQR1XS
SW1710 MoO1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIXMd49KSzVyPUCuNFc2OSCwTR?= NF3WNXlUSU6JRWK=
DEL MkjHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX\JR|UxRTBwMEi4O{BvVQ>? MWnTRW5ITVJ?
AGS MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFXJWVZKSzVyPUCuNFkxOiCwTR?= NH3KZ4hUSU6JRWK=
NCI-H2122 NFLVeWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2TIdGlEPTB;MD6wPVQ3KG6P NY\Q[5E{W0GQR1XS
HSC-4 NUD5TYJpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUDJR|UxRTBwMUCyJI5O NIK0e2tUSU6JRWK=
AM-38 NHjyfJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH3DUoFKSzVyPUCuNVIyKG6P NEK1dXBUSU6JRWK=
769-P MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn[yTWM2OD1yLkGyN{BvVQ>? M17kO3NCVkeHUh?=
RT-112 NVnsdI5JT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV7JdmdIUUN3ME2wMlEzPyCwTR?= NXfSVZVmW0GQR1XS
MCF7 M3fPfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYDiV2p[UUN3ME2wMlE{PiCwTR?= M4rXd3NCVkeHUh?=
IGROV-1 M13yd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NETHbmZKSzVyPUCuNVQ2KG6P NHrM[4VUSU6JRWK=
OCI-AML2 NYH6c5lpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGnCV21KSzVyPUCuNVQ4KG6P MojEV2FPT0WU
NCI-H1299 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEW2SYRKSzVyPUCuNVU4KG6P NIHQXIZUSU6JRWK=
A431 NVH6c2dZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHXSRnhKSzVyPUCuNVg{KG6P MVXTRW5ITVJ?
SW982 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX;2V2dtUUN3ME2wMlIyOyCwTR?= NWjlbZUxW0GQR1XS
BB30-HNC Ml3jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFK0cpRKSzVyPUCuNlMyKG6P NXrPOWtvW0GQR1XS
ACN NWHRVZh1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2DJUWlEPTB;MD6yOFQhdk1? NXjuTI9UW0GQR1XS
647-V M3H1cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn;FTWM2OD1yLkK0PEBvVQ>? NU\ySJR4W0GQR1XS
SK-PN-DW MlrBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEi2eYhKSzVyPUCuNlY3KG6P M4nWT3NCVkeHUh?=
LCLC-97TM1 M2rCUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1;2c2lEPTB;MD6yOlchdk1? M{nVZ3NCVkeHUh?=
LB1047-RCC MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1zyb2lEPTB;MD6yOlkhdk1? NWrl[3FwW0GQR1XS
A2780 MmWyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGjKU3RKSzVyPUCuNlchdk1? M1z1[XNCVkeHUh?=
C-33-A M2XpWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYrJR|UxRTBwMkezJI5O NVjFbZhlW0GQR1XS
NCI-H2228 NFLrWGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1O3OGlEPTB;MD6zNVQhdk1? NXi1OZk4W0GQR1XS
TE-5 Ml3GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUjEXmF7UUN3ME2wMlMyPiCwTR?= MX\TRW5ITVJ?
HC-1 M1\VZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnnETWM2OD1yLkOyO{BvVQ>? M2LiXHNCVkeHUh?=
SK-MES-1 NIXJVZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4PLd2lEPTB;MD6zNlghdk1? NF3QRYNUSU6JRWK=
NCI-H1355 NITZfodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXrJR|UxRTBwM{ixJI5O MXPTRW5ITVJ?
YKG-1 NFPwSZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlrXTWM2OD1yLkSxPUBvVQ>? NGfwflRUSU6JRWK=
RS4-11 NWrlVFlFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYrpO|lpUUN3ME2wMlQ{OyCwTR?= NVuwPVJNW0GQR1XS
Daoy NYfPcmFHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVzXPWlLUUN3ME2wMlQ2PiCwTR?= NUfneXRsW0GQR1XS
A3-KAW MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWLGflJyUUN3ME2wMlU2OSCwTR?= MX3TRW5ITVJ?
SK-MEL-30 NFTWOIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFrkfVBKSzVyPUCuOVU1KG6P NXHjSoFbW0GQR1XS
U031 NWXGfIxVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEf6OFZKSzVyPUCuOVY2KG6P M{WzTHNCVkeHUh?=
SK-LMS-1 NYDRSoZET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFnMT5BKSzVyPUCuOVc5KG6P MoHhV2FPT0WU
ES6 NFPDSIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXXEblJIUUN3ME2wMlU5PiCwTR?= NFm4UWpUSU6JRWK=
EoL-1-cell MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFPGbIpKSzVyPUCuOlE3KG6P NH7xXoFUSU6JRWK=
NCI-H2009 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXzJR|UxRTBwNkG5JI5O M3vaTXNCVkeHUh?=
A4-Fuk NWHUN4p[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mkm4TWM2OD1yLk[yOkBvVQ>? MXjTRW5ITVJ?
KYSE-270 NUP0cWIzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYrET5AzUUN3ME2wMlY{PCCwTR?= M13QUXNCVkeHUh?=
SK-LU-1 MmTOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4e2dmlEPTB;MD62OVUhdk1? MlnOV2FPT0WU
SW872 NVXTRllwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYPJR|UxRTBwN{[1JI5O Mn\yV2FPT0WU
ES8 Mn[zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWq3VJNGUUN3ME2wMlc5KG6P NH70elBUSU6JRWK=
G-402 M1nJU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYHs[nRXUUN3ME2wMlc5PCCwTR?= M1ThPHNCVkeHUh?=
ATN-1 NGnQbYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX3JR|UxRTBwOEC3JI5O NHHycG9USU6JRWK=
DoTc2-4510 NV3BOJpLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3Tab2lEPTB;MD65NFEhdk1? MX;TRW5ITVJ?
MES-SA MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEPzbZRKSzVyPUCuPVA2KG6P M3;CbHNCVkeHUh?=
SF268 NHW2VJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M33vTmlEPTB;MD65Nlchdk1? M{H2e3NCVkeHUh?=
SF539 NV2yNHRwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mk[0TWM2OD1zLkCyJI5O M3\UbnNCVkeHUh?=
NB69 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2P5R2lEPTB;MT6wOUBvVQ>? MVPTRW5ITVJ?
8505C MonkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUPo[pZMUUN3ME2xMlA3KG6P NF[z[FdUSU6JRWK=
CAL-12T NHq3PJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{D3Z2lEPTB;MT6wPEBvVQ>? NHnFc|VUSU6JRWK=
BHY NIPoPJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoTQTWM2OD1zLkG0JI5O MV3TRW5ITVJ?
LB647-SCLC NGfJVYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M162dGlEPTB;MT6xPEBvVQ>? MYHTRW5ITVJ?
CAL-62 NELTTYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX;pb491UUN3ME2xMlIzKG6P NVn5e5NbW0GQR1XS
MEG-01 NVHifJB{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVvJR|UxRTFwMkegcm0> NGL5RYhUSU6JRWK=
MG-63 MnTuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWLQOJF3UUN3ME2xMlM{KG6P M1PxRnNCVkeHUh?=
SW620 NYrEeoJkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmPOTWM2OD1zLkO1JI5O NInK[2JUSU6JRWK=
A388 MmrlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIrXfHJKSzVyPUGuN|Yhdk1? M{TCbnNCVkeHUh?=
BCPAP MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUDJR|UxRTFwNEWgcm0> MWXTRW5ITVJ?
P30-OHK NWXHOJV7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXLJR|UxRTFwNE[gcm0> NIrtcHFUSU6JRWK=
Ca9-22 MkHyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3joemlEPTB;MT61OEBvVQ>? NVy2OWlJW0GQR1XS
VMRC-RCZ MkLCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUXJR|UxRTFwNUSgcm0> MofEV2FPT0WU
LOXIMVI NHPTOmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{XUfmlEPTB;MT62JI5O NIrDW3NUSU6JRWK=
L-540 NWPyWFc2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4LlW2lEPTB;MT62JI5O NEfoTWRUSU6JRWK=
NTERA-S-cl-D1 NIXFXFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVTJR|UxRTFwNkSgcm0> MXLTRW5ITVJ?
MFH-ino M3n0SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV\JR|UxRTFwNk[gcm0> M{fuVXNCVkeHUh?=
Calu-6 M1LuTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWPJR|UxRTFwN{Ogcm0> MlT3V2FPT0WU
HEL MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX7JR|UxRTFwN{mgcm0> MXrTRW5ITVJ?
CAL-33 NEnzOXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYjJR|UxRTFwOEmgcm0> NX\qTmo5W0GQR1XS
HSC-3 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXjJR|UxRTFwOUGgcm0> NXrSOXlJW0GQR1XS
KU812 M3HuUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWfJR|UxRTFwOUGgcm0> MVHTRW5ITVJ?
EB2 NGHqU|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{fEWWlEPTB;Mj6wNUBvVQ>? MXHTRW5ITVJ?
SR MmjRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlXCTWM2OD1{LkGyJI5O NHWye45USU6JRWK=
NCI-H2087 Mlu4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYDvb5JHUUN3ME2yMlE1KG6P M2npUnNCVkeHUh?=
H4 NVqzXm16T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXnJR|UxRTJwMUigcm0> Mn;UV2FPT0WU
EW-1 MkD2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWLBOJQ{UUN3ME2yMlIzKG6P MVjTRW5ITVJ?
MC-IXC NXfNWog{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUPSZVhWUUN3ME2yMlI3KG6P NHLrPWtUSU6JRWK=
NCI-H727 M2nDcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3nuNGlEPTB;Mj61NUBvVQ>? NXzKfJVJW0GQR1XS
MRK-nu-1 M1rvdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGDCfGNKSzVyPUKuOVchdk1? MkDiV2FPT0WU
COLO-668 NF7xT3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHWwUllKSzVyPUKuOlYhdk1? M3zRUHNCVkeHUh?=
CGTH-W-1 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYXWVoxMUUN3ME2yMlczKG6P NEnLTZVUSU6JRWK=
CHP-212 NGHkd|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnfITWM2OD1{Lke1JI5O MV\TRW5ITVJ?
GI-1 M{T1W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUPJR|UxRTJwN{[gcm0> NGC5eI1USU6JRWK=
HCC1806 NWSwNJFkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1jt[mlEPTB;Mj65NUBvVQ>? NGfXcWxUSU6JRWK=
HLE M2fQbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEHrS4JKSzVyPUOgcm0> M1H1TXNCVkeHUh?=
HSC-2 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoLtTWM2OD1|LkCzJI5O Mkn5V2FPT0WU
DMS-273 NHu4[3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlPwTWM2OD1|LkC3JI5O NFK3c4dUSU6JRWK=
DU-4475 Ml6zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFjXZnRKSzVyPUOuNVQhdk1? NFPybpFUSU6JRWK=
LXF-289 NILBb2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXPtZ295UUN3ME2zMlMyKG6P MYPTRW5ITVJ?
PANC-03-27 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHfsbFRKSzVyPUOuOVEhdk1? M1zpNXNCVkeHUh?=
GAMG MnzCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUHaeHg1UUN3ME2zMlc1KG6P Mof1V2FPT0WU
NCI-H522 NWfZUpRpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Moi0TWM2OD12LkO0JI5O Mk\iV2FPT0WU
SW626 M3vyXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mk\5TWM2OD12LkS2JI5O NWXEZ2U1W0GQR1XS
HT-144 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYK0VXZmUUN3ME20MlkzKG6P MXTTRW5ITVJ?
MEL-HO MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1\HcWlEPTB;NT6xOkBvVQ>? MUfTRW5ITVJ?
BE-13 M4Pt[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoHCTWM2OD13LkKxJI5O NX2yOYh6W0GQR1XS
VA-ES-BJ M4TPZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUHJR|UxRTVwMk[gcm0> MmPNV2FPT0WU
NCI-H441 NFjpNFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGfBXVhKSzVyPUWuOkBvVQ>? NI\zToJUSU6JRWK=
KP-4 NEizblhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHWy[Y5KSzVyPUWuOlEhdk1? MUfTRW5ITVJ?
LoVo MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NET5eVNKSzVyPUWuO|Ehdk1? MkO0V2FPT0WU
HT-1080 MonkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFq0VGdKSzVyPUWuPFMhdk1? MlfCV2FPT0WU
GB-1 NWnae2FNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmPwTWM2OD13Lki0JI5O M4LQdXNCVkeHUh?=
IA-LM M374Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NY\XRZhtUUN3ME21MlkyKG6P M1P1dnNCVkeHUh?=
8-MG-BA MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVS0SYZ[UUN3ME21Mlk{KG6P MlzHV2FPT0WU
SK-HEP-1 NWLHW2ZPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmfuTWM2OD14LkG0JI5O NG[yU4tUSU6JRWK=
697 NVXLS4d2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MorCTWM2OD14LkK1JI5O M{j2OXNCVkeHUh?=
KYSE-450 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2fUbmlEPTB;Nj6zNkBvVQ>? MmLPV2FPT0WU
HCC2998 M4HzRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn:zTWM2OD14LkO0JI5O MX;TRW5ITVJ?
HD-MY-Z Moi0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWHKbmM4UUN3ME22MlY5KG6P MnLGV2FPT0WU
OS-RC-2 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH71b2ZKSzVyPU[uOlghdk1? M3H6[HNCVkeHUh?=
SF126 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUPJR|UxRTdwMEWgcm0> NFu5NVVUSU6JRWK=
Ca-Ski MnHsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX;JR|UxRTdwMEmgcm0> MUTTRW5ITVJ?
NCI-H358 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEXBRZBKSzVyPUeuNVYhdk1? MoLTV2FPT0WU
J82 Mn;qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHq2UGxKSzVyPUeuOFEhdk1? MXzTRW5ITVJ?
NCI-H2342 NGnlelNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NU\UemxnUUN3ME23MlY{KG6P NGrxfHdUSU6JRWK=
OVCAR-8 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEHOS5FKSzVyPUeuPUBvVQ>? Mn\0V2FPT0WU
TE-8 NXTwe4kyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2fYSWlEPTB;ODDuUS=> MYjTRW5ITVJ?
ETK-1 Mn[1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYnFcINkUUN3ME24MlA5KG6P M4W2WnNCVkeHUh?=
HAL-01 MlfsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4\remlEPTB;OD6yJI5O Moj6V2FPT0WU
KYSE-150 NG\mbGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3W4[mlEPTB;OD60O{BvVQ>? NH76VpVUSU6JRWK=
NCI-H810 M4nNdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXHBUodSUUN3ME24MlU3KG6P M1TjVHNCVkeHUh?=
ONS-76 NXeyTnhKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGjlWmpKSzVyPUiuOlghdk1? MnzJV2FPT0WU
NMC-G1 NHnhVWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4Lw[GlEPTB;OD63OkBvVQ>? NWPhVJdEW0GQR1XS
C3A MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHzXd2NKSzVyPUiuPFQhdk1? MnHaV2FPT0WU
PA-1 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGDXVm5KSzVyPUiuPVkhdk1? M1;qXnNCVkeHUh?=
SH-4 NVfqOZhqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYDJR|UxRTlwMEKgcm0> NYDsN4NDW0GQR1XS
EFO-27 MmjGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXPJR|UxRTlwMEWgcm0> MVjTRW5ITVJ?
CAPAN-1 MlLpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWLJR|UxRTlwMkOgcm0> M4LtbnNCVkeHUh?=
DU-145 NFH2cmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXnISmxNUUN3ME25MlI6KG6P MVXTRW5ITVJ?
A101D MkDQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn7kTWM2OD17LkO3JI5O NVu0SGNiW0GQR1XS
ST486 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVnJR|UxRTlwNEGgcm0> MUjTRW5ITVJ?
NCI-H1437 NEX2fIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkX6TWM2OD17LkSyJI5O NF:zcIxUSU6JRWK=
HGC-27 M4TDeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVLJR|UxRTlwNjDuUS=> MWPTRW5ITVJ?
8305C NYrES|I3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIHQToxKSzVyPUmuOlQhdk1? MX7TRW5ITVJ?
OCUB-M MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mkn3TWM2OD1zMD6wN{BvVQ>? NVnscpFPW0GQR1XS
COLO-679 MnnqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWPJR|UxRTFyLkC3JI5O MWLTRW5ITVJ?
Detroit562 M3rLVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NELuOJpKSzVyPUGwMlQzKG6P NYjt[Xd4W0GQR1XS
A204 MoTCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUXJR|UxRTFzLkG2JI5O MU\TRW5ITVJ?
NCI-H1734 MkDkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFjL[WVKSzVyPUGxMlI6KG6P M2XtZ3NCVkeHUh?=
MC-CAR NFLld2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWfJR|UxRTFzLkW4JI5O MoXhV2FPT0WU
NCI-H2170 NIPINlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWDGcodvUUN3ME2xNU46PyCwTR?= NEH6[2FUSU6JRWK=
NCI-SNU-5 NWrZ[3pbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWXURmVDUUN3ME2xNk4yOyCwTR?= M4\WZ3NCVkeHUh?=
HCE-T MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlvjTWM2OD1zMj60NkBvVQ>? NEPzSnhUSU6JRWK=
KYSE-180 NHPSRXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV\JR|UxRTF{LkixJI5O MXXTRW5ITVJ?
C8166 NVLzSnhwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MULJR|UxRTF|LkC4JI5O MlfNV2FPT0WU
NCI-H460 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGT0ZoZKSzVyPUGzMlU1KG6P NXXLe2hkW0GQR1XS
SNU-449 MkDIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2L3bWlEPTB;MUOuO|chdk1? NEnMN|FUSU6JRWK=
MDA-MB-468 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEPsN5BKSzVyPUG0MlEzKG6P NH;QOJFUSU6JRWK=
COR-L23 NHLNOVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUPJR|UxRTF2LkGzJI5O Ml3zV2FPT0WU
CTV-1 Mle3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmTxTWM2OD1zND6xOEBvVQ>? Mn;uV2FPT0WU
BL-41 NGXOcmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoLYTWM2OD1zND6zO{BvVQ>? MVjTRW5ITVJ?
IGR-1 NH2yelRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVjJR|UxRTF2LkSyJI5O M2W4WXNCVkeHUh?=
TK10 MkTQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkfETWM2OD1zND60PUBvVQ>? Ml32V2FPT0WU
REH M1y3Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFq5UoRKSzVyPUG0MlUyKG6P NUn3PFcxW0GQR1XS
LU-139 NHT2WYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NE\rPIZKSzVyPUG0MlU6KG6P M3\2SnNCVkeHUh?=
KP-N-YS MmTXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUfZNJREUUN3ME2xOE46PyCwTR?= MWnTRW5ITVJ?
PANC-10-05 MknqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NW\2WJEzUUN3ME2xOU4{QCCwTR?= M{PTb3NCVkeHUh?=
HL-60 NHqzSIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHHifWVKSzVyPUG1MlY6KG6P M{nZS3NCVkeHUh?=
T84 NHvKUJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2rQOWlEPTB;MUWuPVYhdk1? NGGyeHFUSU6JRWK=
RPMI-8226 M3fHRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWPJR|UxRTF4LkCyJI5O MYHTRW5ITVJ?
UM-UC-3 Mm\NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlvSTWM2OD1zNj6xOkBvVQ>? MWjTRW5ITVJ?
TE-10 MkfES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGjjcW1KSzVyPUG2MlIyKG6P MXPTRW5ITVJ?
CAL-148 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3TWNWlEPTB;MUeuNlMhdk1? NETtNWFUSU6JRWK=
BV-173 NFvHXVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnXWTWM2OD1zNz6yO{BvVQ>? Moq2V2FPT0WU
Calu-3 Ml3nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGTIS4FKSzVyPUG3MlI6KG6P NV\LXWtCW0GQR1XS
RPMI-2650 NFjGfYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX3GfFFrUUN3ME2xO{42QSCwTR?= NYfSW|l5W0GQR1XS
MKN45 NXP2e4xMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmW2TWM2OD1zNz63N{BvVQ>? NX\pdW1LW0GQR1XS
NUGC-3 M4LQWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYHZblNsUUN3ME2xPE4{PCCwTR?= NGfxO2FUSU6JRWK=
NCI-H520 MkC3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXzJR|UxRTF6Lke3JI5O NFjCNnlUSU6JRWK=
CCRF-CEM NYW3U2ZGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmXRTWM2OD1zOD64OUBvVQ>? MlnCV2FPT0WU
NCI-H2405 M2KzOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1z6e2lEPTB;MUmuNUBvVQ>? MUPTRW5ITVJ?
ES7 NIrUNphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIjpeJJKSzVyPUG5Mlc3KG6P NVfvc2M{W0GQR1XS
BPH-1 NHzwOnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWPJR|UxRTJyLkK4JI5O M{LxNnNCVkeHUh?=
SAS NFPEW5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXvJR|UxRTJyLkWgcm0> M2jDeXNCVkeHUh?=
HuCCT1 NFfJS25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVzkSWlpUUN3ME2yNE42QCCwTR?= NGT2[XpUSU6JRWK=
LOUCY NX72SGkxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVTJR|UxRTJyLk[2JI5O MlHLV2FPT0WU
NCI-H292 NWDsNJJFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYjJR|UxRTJyLke5JI5O MkXuV2FPT0WU
G-361 NIWwbZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mlq0TWM2OD1{MT6wO{BvVQ>? MVrTRW5ITVJ?
M059J MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGPXXXlKSzVyPUKxMlA5KG6P MVrTRW5ITVJ?
NCI-H1651 NXK2Z3hGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3TxRWlEPTB;MkGuNVEhdk1? MYfTRW5ITVJ?
KALS-1 NX3HRosxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnvCTWM2OD1{MT6zPUBvVQ>? NHvuRmNUSU6JRWK=
DJM-1 NGXYNHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF3zVppKSzVyPUKxMlU6KG6P M2mwNnNCVkeHUh?=
AU565 M3XGbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV7JR|UxRTJzLkizJI5O MmHmV2FPT0WU
HCC38 M2LYc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4fveWlEPTB;MkGuPVUhdk1? MnL2V2FPT0WU
U251 NWDS[oEzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1myR2lEPTB;MkKuNlchdk1? MVzTRW5ITVJ?
ABC-1 NFLOdlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUDJR|UxRTJ{Lk[1JI5O M1TpUHNCVkeHUh?=
SK-NEP-1 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYXJR|UxRTJ{LkmzJI5O NGH2dVhUSU6JRWK=
CESS NVvWc2JkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXTKVGllUUN3ME2yN{4yQSCwTR?= Mli0V2FPT0WU
MIA-PaCa-2 NVvBXIJRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVfJR|UxRTJ|LkO2JI5O MnO1V2FPT0WU
SUP-T1 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEPN[|VKSzVyPUKzMlQ4KG6P MoTGV2FPT0WU
L-428 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEfB[YxKSzVyPUKzMlYzKG6P MknEV2FPT0WU
SW954 MoKzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4jQdWlEPTB;MkOuOlghdk1? NXe3PWZ{W0GQR1XS
HO-1-N-1 MmPGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYrJR|UxRTJ|Lke3JI5O MX7TRW5ITVJ?
CHP-126 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Moi3TWM2OD1{ND6xOEBvVQ>? Mn25V2FPT0WU
HMV-II NIrre4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3XlV2lEPTB;MkSuN|Qhdk1? NWnuOoZRW0GQR1XS
NB10 NGfSeopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYPJR|UxRTJ2LkO3JI5O MUHTRW5ITVJ?
A172 NUHoc3FKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVPSUlVSUUN3ME2yOE44OSCwTR?= NV\uWVljW0GQR1XS
MONO-MAC-6 Mny3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH3xdpBKSzVyPUK0Mlg1KG6P MYXTRW5ITVJ?
NCI-H1650 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXTJR|UxRTJ3LkSgcm0> NUjhXJBSW0GQR1XS
NH-12 M3O1[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NE\le41KSzVyPUK1MlUhdk1? M1j6fHNCVkeHUh?=
ML-2 NGDvb4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3PpeWlEPTB;MkWuO|Qhdk1? NF2xPWtUSU6JRWK=
MZ2-MEL NGi3[4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHr4N4RKSzVyPUK2MlIzKG6P Mn\6V2FPT0WU
COLO-684 NWLzS4RET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIC1VpNKSzVyPUK2MlQyKG6P MWjTRW5ITVJ?
HuP-T4 NFrqVYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnK4TWM2OD1{Nz6zJI5O M4L1TnNCVkeHUh?=
SW837 M4jjVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkmyTWM2OD1{Nz62NkBvVQ>? MmDZV2FPT0WU
MDA-MB-231 NULKWXpNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mni5TWM2OD1{Nz63PEBvVQ>? MYPTRW5ITVJ?
KYSE-140 NGW5dm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkXOTWM2OD1{Nz65NUBvVQ>? M1jLd3NCVkeHUh?=
NOMO-1 NUT0elJST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHnvb4NKSzVyPUK4MlY5KG6P NIPySIZUSU6JRWK=
GP5d NVezOnlvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2XHNGlEPTB;MkiuO|Ihdk1? NHyxN5FUSU6JRWK=
COR-L105 M{T2cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFvzV3BKSzVyPUK5MlQzKG6P NWTCZ3hNW0GQR1XS
LS-411N MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVPJR|UxRTJ7Lki4JI5O NFnuV3BUSU6JRWK=
NY NWHLelBCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHrvZoFKSzVyPUOwMlE5KG6P MlrPV2FPT0WU
NCI-H2030 M1njXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlO4TWM2OD1|MD60OUBvVQ>? MojkV2FPT0WU
CCF-STTG1 NV\nZVdIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUXJR|UxRTNzLkSyJI5O NHjrOINUSU6JRWK=
NCI-H1703 NV:1d5Q2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUDXOXV{UUN3ME2zNU44QCCwTR?= NYf1N5o6W0GQR1XS
TUR MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M17r[2lEPTB;M{KuNFMhdk1? NYDr[nl5W0GQR1XS
NOS-1 NFO4WXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{jnTGlEPTB;M{KuOFQhdk1? NYL5XYgyW0GQR1XS
A2058 NHi4T2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUHJR|UxRTN{LkizJI5O MWfTRW5ITVJ?
LCLC-103H MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIDER|VKSzVyPUOzMlI2KG6P M33iXnNCVkeHUh?=
NCI-H510A MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHvUfW1KSzVyPUOzMlI4KG6P NXrNSFg{W0GQR1XS
BC-1 NX\uVmt6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH63Nm1KSzVyPUOzMlc4KG6P NWTnR5RZW0GQR1XS
SK-CO-1 M4nydmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1vzfGlEPTB;M{SuNFEhdk1? NWfnU|hRW0GQR1XS
A673 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoG3TWM2OD1|ND6xO{BvVQ>? M13tS3NCVkeHUh?=
VM-CUB-1 M4P4WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUPqTo06UUN3ME2zOE43QSCwTR?= NVvjWJV4W0GQR1XS
HH M4DZR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWrJR|UxRTN3LkC2JI5O NFPpdYlUSU6JRWK=
CAL-27 NIm5OXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1LnSWlEPTB;M{WuNVYhdk1? NXnKXmlYW0GQR1XS
NEC8 M4fac2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIPpdYJKSzVyPUO1MlM4KG6P NUHoNYdWW0GQR1XS
BxPC-3 NHvlXXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWXJR|UxRTN4LkmxJI5O MonwV2FPT0WU
SNB75 NFL3W2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEO0dmdKSzVyPUO3MlI1KG6P NH;TbZhUSU6JRWK=
NB13 NEi5VpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkXjTWM2OD1|OD6yN{BvVQ>? NYDWXGV{W0GQR1XS
SK-OV-3 NITVN2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MofTTWM2OD1|OD63OEBvVQ>? MUDTRW5ITVJ?
ME-180 MnLQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWnJR|UxRTN6Lkigcm0> M17YOHNCVkeHUh?=
JiyoyeP-2003 Ml:2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIDVOIVKSzVyPUO5MlM5KG6P NYPRNG5[W0GQR1XS
LU-134-A MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFXoVY5KSzVyPUSwMlAzKG6P NXzLWJBOW0GQR1XS
LS-123 NH7QUmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX\TSZpUUUN3ME20NE4zQCCwTR?= MWDTRW5ITVJ?
COLO-800 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV7JR|UxRTRyLkW2JI5O NFziW3RUSU6JRWK=
LB831-BLC M{HQW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUPJR|UxRTRzLki1JI5O NUTGUVVoW0GQR1XS
NCI-H747 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGPWSJFKSzVyPUSyMlI5KG6P NYrybo9rW0GQR1XS
MZ7-mel NV;HUJBET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX;JR|UxRTR{Lk[2JI5O NH3Qc3pUSU6JRWK=
GT3TKB NVLG[mhiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGjre4hKSzVyPUSyMlczKG6P MVzTRW5ITVJ?
MOLT-16 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH70TZRKSzVyPUSzMlA2KG6P MmnJV2FPT0WU
23132-87 NHHFcoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGTuV45KSzVyPUSzMlA2KG6P NYLlTm4{W0GQR1XS
PF-382 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4nsTGlEPTB;NESuNlIhdk1? NXnyW|lrW0GQR1XS
ES3 MnHlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHj2PWdKSzVyPUS0MlYhdk1? MlTjV2FPT0WU
SW756 NFrjO|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUHJR|UxRTR3LkG0JI5O MoXYV2FPT0WU

他の多くの細胞株試験データをご覧になる場合はこちらをクリックして下さい

アッセイ
Methods Test Index PMID
Western blot
p70S6K1 / p-S6 / HIF-1α ; 

PubMed: 27765914     


Cells were treated with different doses of gemcitabine (0, 1.5 and 2.5 μM), the expression levels of p70S6K1, p-S6 and HIF-1α were determined by Western blotting. GAPDH is used as an internal control.

PARP / Cleaved PARP / Cleaved caspase-3 / phopho-p38 / p38 / p-JNK / JNK / p-c-Jun; 

PubMed: 24409315     


AsPC-1, BxPC-3, and COLO-357 cells were incubated for the indicated times with 100 ng/ml, 10 ng/ml, and 5 ng/ml gemcitabine, respectively, and analyzed by immunoblotting. 

27765914 24409315
Immunofluorescence
Bim1; 

PubMed: 27177084     


Gemcitabine enhanced nuclear accumulation of Bmi1 by immunofluorescence staining. The graphs shown are representative results of three independently repeated experiments. Scale bar, 50 μm.

27177084
Growth inhibition assay
Cell viability; 

PubMed: 27765914     


A and B. Pancreatic adenocarcinoma cells Bxpc-3 (A) and Panc-1 (B) were treated with gemcitabine (GEM) for 48 h at different doses. The cell viability was analyzed by CCK-8 assay, and normalized to cells without gemcitabine treatment. 

27765914
体内試験 Gemcitabine combined with C225 results in growth inhibition, tumor regression, and abrogation of metastasis in L3.6pl tumors established in the pancreas of nude mice. Gemcitabine treatment alone reduces median tumor volume from 538 to 152 mm3. Gemcitabine reduces the production of vascular endothelial growth factor and interleukin 8 in gemcitabine-treated tumors. [2] Gemcitabine is able to dramatically and specifically reduces the number of myeloid suppressor cells found in the spleens of animals bearing large tumors with no significant reductions in CD4(+) T cells, CD8(+) T cells, NK cells, macrophages, or B cells. [4] Gemcitabine combined with curcumin shows significant reductions in volume (P = 0.008 versus control; P = 0.036 versus gemcitabine alone), Ki-67 proliferation index (P = 0.030 versus control), NF-kappaB activation, and expression of NF-kappaB-regulated gene products (cyclin D1, c-myc, Bcl-2, Bcl-xL, cellular inhibitor of apoptosis protein-1, cyclooxygenase-2, matrix metalloproteinase, and vascular endothelial growth factor) compared with tumors from control mice treated with olive oil only. Gemcitabine combined with Curcumin is also highly effective in suppressing angiogenesis as indicated by a decrease in CD31(+) microvessel density. [5]

お薦めの試験操作(参考用のみ)

溶解度 (25°C)

体外 DMSO 52 mg/mL (197.56 mM)
Water 52 mg/mL warmed (197.56 mM)
Ethanol Insoluble
体内 左から(NMPから)右の順に溶剤を製品に加えます(文献ではなく、Selleckの実験によるデータ):
water (warmed)
混合させたのち直ちに使用することを推奨します。
52mg/mL

* 溶解度測定はSelleck技術部門によって行われており、その他文献に示されている溶解度と差異がある可能性がありますが、同一ロットの生産工程で起きる正常な現象ですからご安心ください。

化学情報

分子量 263.2
化学式

C9H11F2N3O4

CAS No. 95058-81-4
Storage powder
in solvent
別名 LY-188011, NSC 613327
Smiles C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F

投与溶媒組成計算器(クリア溶液)

ステップ1:実験データを入力してください。(実験操作によるロスを考慮し、動物数を1匹分多くして計算・調製することを推奨します)
投与量 mg/kg 動物平均体重 g 投与体積(動物毎) ul 動物数
ステップ2:投与溶媒の組成を入力してください。(ロット毎に適した溶解組成が異なる場合があります。詳細については弊社までお問い合わせください)
% DMSO % % Tween 80 % ddH2O
計算リセット

便利ツール

モル濃度計算器

モル濃度計算器

求めたい質量、体積または濃度を計算してください。

質量 (mg) = 濃度 (mM) x 体積 (mL) x 分子量 (g/mol)

モル濃度計算器方程式

  • 質量
    濃度
    体積
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備するために必要な希釈率を計算してください。Selleck希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 入力 出力 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

質量 濃度 体積 分子量

臨床試験

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04383119 Not yet recruiting Drug: Trabectedin|Drug: Gemcitabine Leiomyosarcoma of Ovary|Soft Tissue Sarcoma Italian Sarcoma Group|PharmaMar September 1 2020 Phase 2
NCT04521686 Recruiting Drug: LY3410738 Cholangiocarcinoma|Chondrosarcoma|Glioma|Any Solid Tumor Loxo Oncology Inc.|Eli Lilly and Company August 2020 Phase 1
NCT04338763 Not yet recruiting Drug: RP72|Drug: Gemcitabine Pancreatic Cancer|Pancreatic Cancer Non-resectable|Pancreatic Cancer Metastatic Rise Biopharmaceuticals Inc.|Amarex Clinical Research April 30 2020 Phase 1

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

  • * 必須

よくある質問(FAQ)

  • 質問1:

    What is the difference between gemcitabine(S1714 ) and Gemcitabine HCl (S1149)?

  • 回答:

    Gemcitabine HCl is the HCl salt form of Gemcitabine. They have the same biological activities. The free base(S1714) dissolves better in DMSO, and the hydrochloride (S1149) dissolves better in water.

DNA/RNA Synthesisシグナル伝達経路

相関DNA/RNA Synthesis製品

Tags: Gemcitabine を買う | Gemcitabine ic50 | Gemcitabine 供給者 | Gemcitabine を購入する | Gemcitabine 費用 | Gemcitabine 生産者 | オーダーGemcitabine | Gemcitabine 化学構造 | Gemcitabine 分子量 | Gemcitabine 代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID